ClinicalTrials.gg
CompletedNCT00466167Updated Jul 8, 2014Results posted

Pivotal Study in Advanced Parkinsons Disease Patients

A Phase 3 interventional study of Pramipexol Extended Release and Pramipexol Immediate Release in Parkinson Disease, sponsored by Boehringer Ingelheim. Completed at 76 sites in 14 countries. Open to participants aged 32 Years and older. Per ClinicalTrials.gov, last updated 2014-07-08.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
517
Ages
32 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 26 studies testing pramipexole in Parkinson Disease — none open to participants now, none under way, none of them phase 3. Pramipexole · Parkinson Disease.

Enrollment
5th of 26
517 · median 224
Started
2007
with 4 others
Phase 3
11 of 26
none open now
Registered
9th of 26
by date
Lead sponsor
16 of 26
Boehringer Ingelheim

Among the 26 studies testing pramipexole in Parkinson Disease, this one is the 5th largest by enrollment, is one of 5 that started in 2007, is one of 11 in phase 3, and was the 9th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

None of the 26 studies testing pramipexole in Parkinson Disease is open now. The open studies under Parkinson Disease, anywhere →

About pramipexole

Pramipexole: first FDA approval 1997 (MIRAPEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 750 Parkinson Disease studies recruiting now, 312 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 190 take healthy volunteers.

This study: 32 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 26 studies testing pramipexole in Parkinson Disease as a file.
02

Study summary

The general aim of this trial is to determine the efficacy (as measured by the change from baseline to the end of the maintenance phase in the total score for Unified Parkinsons Disease Rating Scale Parts II and III combined), safety, and tolerability of pramipexole ER, in daily doses from 0.375 milligram to 4.5 milligram once a day, in comparison to placebo, in Levodopa combined with a Dopa-Decarboxylase-inhibitor treated Parkinson patients with advanced Parkinsons Disease and motor fluctuations.

In addition, a numerical comparison of the efficacy of pramipexole extended release versus pramipexole immediate release will be done.

The efficacy of pramipexole immediate release will also be compared to placebo, for assay sensitivity.

03

Conditions studied

  • Parkinson Disease

Browse trials for

04

Who can participate

Ages eligible
32 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patient with advanced idiopathic Parkinsons disease confirmed by at least two of the following signs: resting tremor, bradykinesia, rigidity.
  2. Parkinsons disease diagnosed for at least 2 years.
  3. Patients 30 years of age or older at the time of diagnosis.
  4. Modified Hoehn and Yahr stage of 2 to 4 at on-time.
  5. Treatment with standard or controlled release Levodopa combined with a Dopa-Decarboxylase-inhibitor, or with Levodopa combined with a Dopa-Decarboxylase-inhibitor/entacapone, at an optimised dose according to investigators judgement, this dose being stable for at least 4 weeks prior to baseline visit.
  6. Motor fluctuations, with at least 2 cumulative hours of off-time every day during waking hours (documented on a patient diary completed for 2 consecutive days before baseline visit).
  7. Patient willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures. In particular, after training, it has to be documented at baseline visit that the patient is able to recognise the off-time and on-time periods during waking hours and that the patient (or a family member or a guardian) is able to record them accurately in the patient diary.
  8. Signed obtained before any study procedures are carried out (in accordance with International Conference on Harmonisation-Good Clinical Practice guidelines and local legislation).

Exclusion criteria

Exclusion Criteria:

  1. Atypical parkinsonian syndromes due to drugs, metabolic disorders, encephalitis or degenerative diseases
  2. Dementia, as defined by a score \< 24 at screening visit
  3. Any psychiatric disorder according to 4th edition criteria that could prevent compliance or completion of the study and/or put the patient at risk if he/she takes part in the study
  4. History of psychosis, except history of drug induced hallucinations
  5. History of deep brain stimulation
  6. abnormalities at screening visit
  7. Clinically significant hypotension and/or symptomatic orthostatic hypotension at screening or baseline visit
  8. Malignant melanoma or history of previously treated malignant melanoma
  9. Any other clinically significant disease, whether treated or not, that could put the patient at risk or could prevent compliance or completion of the study
  10. Pregnancy or breast-feeding
  11. Sexually active female of not using a medically approved method of for at least one month prior to the screening visit and throughout the study period
  12. Serum levels of (Serum Glutamic-Oxaloacetic Transaminase), Alanine Aminotransferase (Serum Glutamic Pyruvic Transaminase), alkaline phosphatases or > 2
  13. Patients with a \< 50 millilitres/minute
  14. Any dopamine agonist (including pramipexole) within 4 weeks prior to baseline visit
  15. Any medication with central dopaminergic antagonist activity within 4 weeks prior to the baseline visit
  16. Any of the following drugs within 4 weeks prior to baseline visit: methylphenidate, cinnarizine, amphetamines
  17. Flunarizine within 3 months prior to baseline visit
  18. Known to pramipexole or its
  19. Drug abuse according to investigators judgement, within 2 years prior to screening
  20. Participation in other drug studies, or use of other investigational drugs within one month or five times the half-life of the investigational drug (whichever is longer) prior to baseline visit
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Intervention model
Parallel assignment
Enrollment
517 participants (actual)

Study arms

  • Other
    Pramipexole ER

    Drug: Pramipexol Extended Release

  • Other
    Pramipexole IR

    Drug: Pramipexol Immediate Release

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Parts II+III Score at Week 18

    UPDRS II+III total score on Full Analysis Set (FAS)with LOCF (Last observation carried forward), week 18 - baseline, UPDRS II+III ranging from 0 (normal) to 160 (severe). UPDRS part II measures activities of daily living, part III measures motor symptoms

    Time frame: baseline and week 18

Secondary outcomes

  1. Change From Baseline in Percentage Off-time at Week 18

    Percentage off-time based on patient diary data, percentage ranging from 0 (best case) to 100 (worst case). Off-time describes a period when the patient experiences increased parkinsonian symptoms (e.g. immobility or inability to move with ease).

    Time frame: baseline and week 18

  2. Change From Baseline in Percentage On-time Without Dyskinesia at Week 18

    Percentage on-time based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.

    Time frame: baseline and week 18

  3. Change From Baseline in Percentage On-time With Non-troublesome Dyskinesia at Week 18

    Percentage on-time with non-troublesome dyskinesia based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.

    Time frame: baseline and week 18

  4. Change From Baseline in Percentage On-time With Troublesome Dyskinesia at Week 18

    Percentage on-time with troublesome dyskinesia based on patient diary data, percentage ranging from 0 (best case) to 100 (worst case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.

    Time frame: baseline and week 18

  5. Clinical Global Impression - Global Improvement (CGI-I) Responder

    CGI-I scores ranging from '1' (very much improved) to '7' (very much worse), CGI-I responder have scoring of 1 or 2 (at least much improved)

    Time frame: after 18 weeks of treatment

  6. Response in Patient Global Impression (PGI-I)

    PGI-I scores ranging from '1' (very much better) to '7' (very much worse), PGI-I responder have scoring 1 or 2 (at least much better)

    Time frame: after 18 weeks of treatment

  7. Change From Baseline in UPDRS I Score After 18 Weeks

    UPDRS I ranging from 0 (normal) to 16 (severe). UPDRS I measures Mentation, Behavior and Mood

    Time frame: baseline and 18 weeks

  8. Change From Baseline in UPDRS II Score After 18 Weeks, Average at on and Off-period

    UPDRS II ranging from 0 (normal) to 52 (severe). UPDRS Part II is calculated as the average of UPDRS part II at on and UPDRS part II at off-period for each of the 13 activities.

    Time frame: baseline and 18 weeks

  9. Change From Baseline in UPDRS III Score After 18 Weeks

    UPDRS III ranging from 0 (normal) to 108 (severe). UPDRS part III measures motor symptoms

    Time frame: baseline and 18 weeks

  10. Change From Baseline in UPDRS IV Score After 18 Weeks

    UPDRS IV ranging from 0 (normal) to 23 (severe). UPDRS IV measures complications of therapy

    Time frame: baseline and 18 weeks

  11. Change From Baseline in Beck's Depression Inventory (BDI) After 18 Weeks

    ranging from 0 (best case) to 63 (worst case)

    Time frame: baseline and 18 weeks

  12. Change From Baseline in Parkinson's Disease Sleep Scale (PDSS) After 18 Weeks

    ranging from 0 (worst case) to 150 (best case)

    Time frame: baseline and 18 weeks

  13. Change From Baseline in Parkinson's Disease Quality of Life Questionnaire 39 After 18 Weeks

    Ranging from 0 (best case) to 156 (worst case)

    Time frame: baseline and 18 weeks

  14. Change From Baseline in European Quality of Life (EuroQol) Scale After 18 Weeks

    ranging from 0 (worst case) to 100 (best case)

    Time frame: baseline and 18 weeks

  15. Change From Baseline in 11-point Likert Scale for Pain Related to PD at Week 18

    Likert scale is a method used for the measurement of pain. The patients were asked to rate their pain related to PD by ticking the number that best described their pain on the average in the previous week, from zero for "no pain" to ten for "unbearable pain".

    Time frame: baseline and week 18

  16. Clinically Significant Abnormalities: Clinical Laboratory Evaluations (Biochemistry and Haematology)

    Time frame: baseline and week 18

07

Results

Posted Feb 8, 2010

Participant flow

Participant flow — Overall Study
MilestonePramipexole ERPramipexole IRPlacebo
Started165175178
Completed145163157
Not completed201221
Withdrew: Adverse event887
Withdrew: Lack of efficacy203
Withdrew: Protocol violation112
Withdrew: Lost to follow-up322
Withdrew: Withdrawal by subject416
Withdrew: Patient did not meet inclusion criteria101
Withdrew: Not treated100

Outcome measures

PrimaryChange From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Parts II+III Score at Week 18

UPDRS II+III total score on Full Analysis Set (FAS)with LOCF (Last observation carried forward), week 18 - baseline, UPDRS II+III ranging from 0 (normal) to 160 (severe). UPDRS part II measures activities of daily living, part III measures motor symptoms

Time frame:
baseline and week 18
Reported as:
Least squares mean · Percentage of change from baseline
Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Parts II+III Score at Week 18
Percentage of change from baselinePramipexole ERPramipexole IRPlacebo
Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Parts II+III Score at Week 18-11.0 ± 1.0-12.8 ± 0.9-6.1 ± 0.9
Statistical analysis
  • Pramipexole ER vs Placebo · ANCOVA · p = 0.0001 · Adjusted mean difference from placebo: 4.9 · 95% CI 2.4 to 7.4
  • Pramipexole IR vs Placebo · ANCOVA · p = <.0001 · Adjusted mean difference from placebo: 6.6 · 95% CI 4.2 to 9.1
SecondaryChange From Baseline in Percentage Off-time at Week 18

Percentage off-time based on patient diary data, percentage ranging from 0 (best case) to 100 (worst case). Off-time describes a period when the patient experiences increased parkinsonian symptoms (e.g. immobility or inability to move with ease).

Time frame:
baseline and week 18
Reported as:
Least squares mean · Percentage of off-time
Change From Baseline in Percentage Off-time at Week 18
Percentage of off-timePramipexole ERPramipexole IRPlacebo
Change From Baseline in Percentage Off-time at Week 18-13.3 ± 1.4-15.9 ± 1.3-8.8 ± 1.3
Statistical analysis
  • Pramipexole ER vs Placebo · ANCOVA · p = 0.0122 · Adjusted mean difference from placebo: 4.5 · 95% CI 1.0 to 7.9
  • Pramipexole IR vs Placebo · ANCOVA · p = <.0001 · Adjusted mean difference from placebo: 7.1 · 95% CI 3.7 to 10.5
SecondaryChange From Baseline in Percentage On-time Without Dyskinesia at Week 18

Percentage on-time based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.

Time frame:
baseline and week 18
Reported as:
Least squares mean · Percentage of on-time without dyskinesia
Change From Baseline in Percentage On-time Without Dyskinesia at Week 18
Percentage of on-time without dyskinesiaPramipexole ERPramipexole IRPlacebo
Change From Baseline in Percentage On-time Without Dyskinesia at Week 1811.9 ± 1.712.6 ± 1.78.9 ± 1.6
SecondaryChange From Baseline in Percentage On-time With Non-troublesome Dyskinesia at Week 18

Percentage on-time with non-troublesome dyskinesia based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.

Time frame:
baseline and week 18
Reported as:
Least squares mean · Percentage of on-time
Change From Baseline in Percentage On-time With Non-troublesome Dyskinesia at Week 18
Percentage of on-timePramipexole ERPramipexole IRPlacebo
Change From Baseline in Percentage On-time With Non-troublesome Dyskinesia at Week 181.9 ± 1.23.9 ± 1.21.0 ± 1.2
SecondaryChange From Baseline in Percentage On-time With Troublesome Dyskinesia at Week 18

Percentage on-time with troublesome dyskinesia based on patient diary data, percentage ranging from 0 (best case) to 100 (worst case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.

Time frame:
baseline and week 18
Reported as:
Least squares mean · Percentage of on-time
Change From Baseline in Percentage On-time With Troublesome Dyskinesia at Week 18
Percentage of on-timePramipexole ERPramipexole IRPlacebo
Change From Baseline in Percentage On-time With Troublesome Dyskinesia at Week 18-0.8 ± 0.5-0.8 ± 0.5-1.0 ± 0.5
SecondaryClinical Global Impression - Global Improvement (CGI-I) Responder

CGI-I scores ranging from '1' (very much improved) to '7' (very much worse), CGI-I responder have scoring of 1 or 2 (at least much improved)

Time frame:
after 18 weeks of treatment
Reported as:
Number · Participants
Clinical Global Impression - Global Improvement (CGI-I) Responder
ParticipantsPramipexole ERPramipexole IRPlacebo
Responder788856
Non-Responder8281115
SecondaryResponse in Patient Global Impression (PGI-I)

PGI-I scores ranging from '1' (very much better) to '7' (very much worse), PGI-I responder have scoring 1 or 2 (at least much better)

Time frame:
after 18 weeks of treatment
Reported as:
Number · Participants
Response in Patient Global Impression (PGI-I)
ParticipantsPramipexole ERPramipexole IRPlacebo
Responder607647
Non-Responder10196127
SecondaryChange From Baseline in UPDRS I Score After 18 Weeks

UPDRS I ranging from 0 (normal) to 16 (severe). UPDRS I measures Mentation, Behavior and Mood

Time frame:
baseline and 18 weeks
Reported as:
Median · Units on a scale
Change From Baseline in UPDRS I Score After 18 Weeks
Units on a scalePramipexole ERPramipexole IRPlacebo
Change From Baseline in UPDRS I Score After 18 Weeks0 (-1.0 to 0.0)0 (-1.0 to 0.0)0 (-1.0 to 0.0)
SecondaryChange From Baseline in UPDRS II Score After 18 Weeks, Average at on and Off-period

UPDRS II ranging from 0 (normal) to 52 (severe). UPDRS Part II is calculated as the average of UPDRS part II at on and UPDRS part II at off-period for each of the 13 activities.

Time frame:
baseline and 18 weeks
Reported as:
Least squares mean · Units on a scale
Change From Baseline in UPDRS II Score After 18 Weeks, Average at on and Off-period
Units on a scalePramipexole ERPramipexole IRPlacebo
Change From Baseline in UPDRS II Score After 18 Weeks, Average at on and Off-period-2.7 ± 0.3-3.6 ± 0.3-1.9 ± 0.3
SecondaryChange From Baseline in UPDRS III Score After 18 Weeks

UPDRS III ranging from 0 (normal) to 108 (severe). UPDRS part III measures motor symptoms

Time frame:
baseline and 18 weeks
Reported as:
Least squares mean · Units on a scale
Change From Baseline in UPDRS III Score After 18 Weeks
Units on a scalePramipexole ERPramipexole IRPlacebo
Change From Baseline in UPDRS III Score After 18 Weeks-8.3 ± 0.7-9.2 ± 0.7-4.3 ± 0.7
SecondaryChange From Baseline in UPDRS IV Score After 18 Weeks

UPDRS IV ranging from 0 (normal) to 23 (severe). UPDRS IV measures complications of therapy

Time frame:
baseline and 18 weeks
Reported as:
Least squares mean · Units on a scale
Change From Baseline in UPDRS IV Score After 18 Weeks
Units on a scalePramipexole ERPramipexole IRPlacebo
Change From Baseline in UPDRS IV Score After 18 Weeks-0.8 ± 0.2-0.9 ± 0.2-0.6 ± 0.2
SecondaryChange From Baseline in Beck's Depression Inventory (BDI) After 18 Weeks

ranging from 0 (best case) to 63 (worst case)

Time frame:
baseline and 18 weeks
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Beck's Depression Inventory (BDI) After 18 Weeks
Units on a scalePramipexole ERPramipexole IRPlacebo
Change From Baseline in Beck's Depression Inventory (BDI) After 18 Weeks-3.2 ± 0.5-4.0 ± 0.5-2.8 ± 0.5
SecondaryChange From Baseline in Parkinson's Disease Sleep Scale (PDSS) After 18 Weeks

ranging from 0 (worst case) to 150 (best case)

Time frame:
baseline and 18 weeks
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Parkinson's Disease Sleep Scale (PDSS) After 18 Weeks
Units on a scalePramipexole ERPramipexole IRPlacebo
Change From Baseline in Parkinson's Disease Sleep Scale (PDSS) After 18 Weeks8.1 ± 1.88.9 ± 1.74.9 ± 1.7
SecondaryChange From Baseline in Parkinson's Disease Quality of Life Questionnaire 39 After 18 Weeks

Ranging from 0 (best case) to 156 (worst case)

Time frame:
baseline and 18 weeks
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Parkinson's Disease Quality of Life Questionnaire 39 After 18 Weeks
Units on a scalePramipexole ERPramipexole IRPlacebo
Change From Baseline in Parkinson's Disease Quality of Life Questionnaire 39 After 18 Weeks-9.1 ± 1.9-13.1 ± 1.8-6.2 ± 1.8
SecondaryChange From Baseline in European Quality of Life (EuroQol) Scale After 18 Weeks

ranging from 0 (worst case) to 100 (best case)

Time frame:
baseline and 18 weeks
Reported as:
Least squares mean · Units on a scale
Change From Baseline in European Quality of Life (EuroQol) Scale After 18 Weeks
Units on a scalePramipexole ERPramipexole IRPlacebo
Change From Baseline in European Quality of Life (EuroQol) Scale After 18 Weeks5.8 ± 1.47.6 ± 1.34.3 ± 1.3
SecondaryChange From Baseline in 11-point Likert Scale for Pain Related to PD at Week 18

Likert scale is a method used for the measurement of pain. The patients were asked to rate their pain related to PD by ticking the number that best described their pain on the average in the previous week, from zero for "no pain" to ten for "unbearable pain".

Time frame:
baseline and week 18
Reported as:
Least squares mean · units on a scale
Change From Baseline in 11-point Likert Scale for Pain Related to PD at Week 18
units on a scalePramipexole ERPramipexole IRPlacebo
Change From Baseline in 11-point Likert Scale for Pain Related to PD at Week 18-0.4 ± 0.2-1.0 ± 0.2-0.3 ± 0.2
SecondaryClinically Significant Abnormalities: Clinical Laboratory Evaluations (Biochemistry and Haematology)
Time frame:
baseline and week 18
Reported as:
Number · participants
Clinically Significant Abnormalities: Clinical Laboratory Evaluations (Biochemistry and Haematology)
participantsPramipexole ERPramipexole IRPlacebo
Haematocrit - decrease2 (26.8 to 43.5)3 (32.4 to 48.8)1 (13.5 to 26.9)
Haemoglobin - decrease253
Red blood cell ct - decrease101
Eosinophils - Increase321
Neut.,poly. (segs),absol. - decrease010
Sodium - decrease020
GGT - increase101
Glucose - decrease101
Glucose - increase021
Triglyceride - increase235
Weight - decrease031
Blood pressure - increase120
Blood pressure - decrease001

Adverse events

Collected over From the first dose of trial medication onwards up to the end of the trial (up to 34 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—15/178 (8.4%)74/178 (41.6%)
Pramipexole ER—8/164 (4.9%)73/164 (44.5%)
Pramipexole IR—11/175 (6.3%)90/175 (51.4%)
Most frequent serious events
Showing 10 of 50
Most frequent serious events
EventPlaceboPramipexole ERPramipexole IR
Hallucination, visualPsychiatric disorders0/1782/1640/175
InsomniaPsychiatric disorders0/1780/1642/175
FallInjury, poisoning and procedural complications0/1780/1642/175
BronchitisInfections and infestations0/1781/1640/175
DelusionPsychiatric disorders0/1781/1641/175
Depressed level of consciousnessNervous system disorders0/1781/1640/175
Disturbance in attentionNervous system disorders0/1781/1640/175
PresyncopeNervous system disorders0/1781/1640/175
HypotensionVascular disorders0/1781/1640/175
BronchospasmRespiratory, thoracic and mediastinal disorders0/1781/1640/175
Most frequent other events
Showing 10 of 11
Most frequent other events
EventPlaceboPramipexole ERPramipexole IR
DyskinesiaNervous system disorders16/17828/16434/175
SomnolenceNervous system disorders29/17824/16430/175
NauseaGastrointestinal disorders19/17818/16420/175
DizzinessNervous system disorders9/1789/16419/175
HeadacheNervous system disorders5/17814/1649/175
NasopharyngitisInfections and infestations12/1783/1647/175
ConstipationGastrointestinal disorders9/17811/16410/175
HallucinationPsychiatric disorders2/1789/16410/175
VomitingGastrointestinal disorders5/1782/16410/175
AnorexiaMetabolism and nutrition disorders4/1789/1642/175

Baseline characteristics

Age, Continuous
Age, Continuous(years)Pramipexole ERPramipexole IRPlaceboTotal
Mean61.6 ± 9.762.0 ± 10.360.9 ± 9.761.5 ± 9.9
Sex: Female, Male
Sex: Female, Male(Participants)Pramipexole ERPramipexole IRPlaceboTotal
Female727784233
Male929894284
08

Study locations

76 sites
  • 248.525.43005 Boehringer Ingelheim Investigational Site
    Linz, Austria
  • 248.525.42003 Boehringer Ingelheim Investigational Site
    Pardubice, Czech Republic
  • 248.525.42001 Boehringer Ingelheim Investigational Site
    Praha, Czech Republic
  • 248.525.42005 Boehringer Ingelheim Investigational Site
    Rakovnik, Czech Republic
  • 248.525.42002 Boehringer Ingelheim Investigational Site
    Rychnov nad Kneznou, Czech Republic
  • 248.525.42004 Boehringer Ingelheim Investigational Site
    Valasske Mezirici, Czech Republic
  • 248.525.36005 Boehringer Ingelheim Investigational Site
    Györ, Hungary
  • 248.525.36003 Boehringer Ingelheim Investigational Site
    Kecskemét, Hungary
  • 248.525.36006 Boehringer Ingelheim Investigational Site
    Szeged, Hungary
  • 248.525.36004 Boehringer Ingelheim Investigational Site
    Veszprem, Hungary
  • 248.525.91004 National Institute of Mental Health & Neuro Sciences
    Bangalore, India
  • 248.525.91002 Apollo Hospital
    Chennai, India
  • 248.525.91001 Institute of Human Behaviour & Allied Sciences
    Delhi, India
  • 248.525.91003 Nizam's Institute of Medical Sciences
    Hyderabad, India
  • 248.525.91007 Boehringer Ingelheim Investigational Site
    Indore, India
  • 248.525.91005 Mallikatta Neuro Research Center
    Karnataka, India
  • 248.525.91006 King Edward Memorial Hospital & Research Centre
    Pune, India
  • 248.525.39001 Policlinico di Catania
    Catania, Italy
  • 248.525.39010 Campus Universitario Germaneto
    Catanzaro, Italy
  • 248.525.39009 Ce.S.I.
    Chieti, Italy
  • 248.525.39007 Ospedale della Misericordia
    Grosseto, Italy
  • 248.525.39002 Università Federico II
    Napoli, Italy
  • 248.525.39008 Azienda Ospedaliera Pisana- Università degli Studi di Pisa
    Pisa, Italy
  • 248.525.39005 Università La Sapienza di Roma
    Roma, Italy
  • 248.525.39011 Policlinico Tor Vergata
    Roma, Italy
  • 248.525.82001 Boehringer Ingelheim Investigational Site
    Gyeonggi-do, Korea, Republic of
  • 248.525.82008 Boehringer Ingelheim Investigational Site
    Kyeonggi-do, Korea, Republic of
  • 248.525.82007 Boehringer Ingelheim Investigational Site
    Pusan, Korea, Republic of
  • 248.525.82002 Boehringer Ingelheim Investigational Site
    Seoul, Korea, Republic of
  • 248.525.82003 Boehringer Ingelheim Investigational Site
    Seoul, Korea, Republic of
  • 248.525.82004 Boehringer Ingelheim Investigational Site
    Seoul, Korea, Republic of
  • 248.525.82005 Boehringer Ingelheim Investigational Site
    Seoul, Korea, Republic of
  • 248.525.82006 Boehringer Ingelheim Investigational Site
    Seoul, Korea, Republic of
  • 248.525.63210 Makati Medical Center
    Makati City, Philippines
  • 248.525.63202 Chinese General Hospital
    Manila, Philippines
  • 248.525.63205 Jose Reyes Memorial Medical Center
    Manila, Philippines
  • 248.525.63206 Metropolitan Medical Center
    Manila, Philippines
  • 248.525.63207 Manila Doctors Hospital
    Manila, Philippines
  • 248.525.63201 The Medical City
    Pasig, Philippines
  • 248.525.63204 St Lukes Medical Center
    Quezon, Philippines
  • 248.525.63208 University of the East Ramon Magsaysay Memorial Medical Ctr
    Quezon, Philippines
  • 248.525.48001 Boehringer Ingelheim Investigational Site
    Gdansk, Poland
  • 248.525.48003 Boehringer Ingelheim Investigational Site
    Krakow, Poland
  • 248.525.48002 Wolski Hospital Dr. Anna Gostynska
    Warsaw, Poland
  • 248.525.07001 Boehringer Ingelheim Investigational Site
    Moscow, Russian Federation
  • 248.525.07002 Boehringer Ingelheim Investigational Site
    Moscow, Russian Federation
  • 248.525.07003 Boehringer Ingelheim Investigational Site
    Moscow, Russian Federation
  • 248.525.07004 Boehringer Ingelheim Investigational Site
    Moscow, Russian Federation
  • 248.525.07007 Boehringer Ingelheim Investigational Site
    Moscow, Russian Federation
  • 248.525.07005 Boehringer Ingelheim Investigational Site
    St. Petersburg, Russian Federation
  • 248.525.07006 Boehringer Ingelheim Investigational Site
    St. Petersburg, Russian Federation
  • 248.525.42104 Boehringer Ingelheim Investigational Site
    Bratislava, Slovakia
  • 248.525.42105 Boehringer Ingelheim Investigational Site
    Bratislava, Slovakia
  • 248.525.42103 Boehringer Ingelheim Investigational Site
    Dubnica nad Vahom, Slovakia
  • 248.525.42101 Boehringer Ingelheim Investigational Site
    Trnava, Slovakia
  • 248.525.34001 Boehringer Ingelheim Investigational Site
    Alcorcon (Madrid), Spain
  • 248.525.34003 Boehringer Ingelheim Investigational Site
    Barcelona, Spain
  • 248.525.34004 Boehringer Ingelheim Investigational Site
    Barcelona, Spain
  • 248.525.34005 Boehringer Ingelheim Investigational Site
    Madrid, Spain
  • 248.525.34002 Boehringer Ingelheim Investigational Site
    San Cugat del Valles (Barcelona), Spain
  • 248.525.34008 Boehringer Ingelheim Investigational Site
    Tarrasa (Barcelona), Spain
  • 248.525.46005 Boehringer Ingelheim Investigational Site
    Malmö, Sweden
  • 248.525.46002 Boehringer Ingelheim Investigational Site
    Nyköping, Sweden
  • 248.525.46001 Boehringer Ingelheim Investigational Site
    Stockholm, Sweden
  • 248.525.46004 Boehringer Ingelheim Investigational Site
    Stockholm, Sweden
  • 248.525.38003 Boehringer Ingelheim Investigational Site
    Dnipropetrovsk, Ukraine
  • 248.525.38006 Boehringer Ingelheim Investigational Site
    Kharkiv, Ukraine
  • 248.525.38002 Boehringer Ingelheim Investigational Site
    Kiev, Ukraine
  • 248.525.38004 Boehringer Ingelheim Investigational Site
    Kiev, Ukraine
  • 248.525.38005 Boehringer Ingelheim Investigational Site
    Zaporizhzhya, Ukraine
  • 248.525.38001 Boehringer Ingelheim Investigational Site
    Zaporozhye, Ukraine
  • 248.525.44005 Boehringer Ingelheim Investigational Site
    Barnsley, United Kingdom
  • 248.525.44007 Boehringer Ingelheim Investigational Site
    Blackburn, United Kingdom
  • 248.525.44002 Boehringer Ingelheim Investigational Site
    London, United Kingdom
  • 248.525.44004 Boehringer Ingelheim Investigational Site
    Norwich, United Kingdom
  • 248.525.44003 Boehringer Ingelheim Investigational Site
    Salford, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2007 and a primary completion of Nov 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2010, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2007
First posted
Apr 27, 2007
Start
Apr 2007
Primary completionActual
Nov 2008
Results first posted
Feb 8, 2010
Last update
Jul 8, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00466167
Responsible party
Sponsor
First posted
Apr 27, 2007
Start date
Apr 2007
Primary completion
Nov 2008
Results posted
Feb 8, 2010
Last update
Jul 8, 2014

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pramipexole

Start the discussion